Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the potential therapeutic effects of targeting the endocannabinoid system for chemotherapy-induced peripheral neuropathy and reports no new clinical results, highlighting the need for ongoing research.

This review discusses pharmacologic treatment options for muscle-related pain conditions and notes that there is strong evidence for the efficacy of tricyclic antidepressants and muscle relaxants in specific myofascial pain syndromes, but not universally.

This article discusses the history and terminology of toxic epidermal necrolysis but reports no new clinical results.

This review examines the use and efficacy of Panax ginseng in various clinical settings, noting that clinical trial outcomes vary widely based on study conditions and ginseng types; no new results are reported.

This review discusses the pharmacological properties and analytical methods for determining fluconazole but reports no new experimental findings.

This review discusses adverse cutaneous drug reactions associated with antidepressants and provides guidance on managing these reactions, but it reports no new clinical findings; the authors recommend cautious use and alternative treatment if reactions occur.

This review discusses the complex interplay between the nervous system and skin conditions, highlighting various treatment strategies, but reports no new research findings.

This review provides practical guidelines for managing psychodermatologic disorders and concludes that psychopharmacologic agents offer a useful option for treatment, considering the underlying psychopathologic condition.

The authors describe drug repurposing as a promising strategy for finding new uses for existing drugs, noting it is efficient, cost-effective, and poses lower risks than traditional drug discovery processes, potentially aiding in the treatment of rare and difficult-to-treat diseases.

This article reviews behavioral dermatology, highlighting the importance of integrating physiological, social, and environmental factors in managing dermatologic conditions with behavioral components, but reports no new clinical results.

This review discusses psychocutaneous syndromes, detailing their classifications and management strategies, but reports no new clinical findings; it underscores dermatologists' role in these cases.

This article reviews the impact of different forms of alopecia on patients with systemic autoimmune diseases and reports no new clinical findings; it emphasizes the need for attentive management of alopecia-related symptoms.

In this study, 14 out of 15 women with scalp dysesthesia also had cervical spine disease, and gabapentin improved symptoms for some patients.

This review discusses cutaneous adverse effects of psychotropic medications and reports no new findings, emphasizing the importance of psychiatrists being aware of these potential skin reactions.

This study found that none of the nine minoxidil-treated autopsy cases showed cardiac pathology attributable to minoxidil, suggesting no direct link between the drug and specific human cardiac lesions.

This review discusses trichotillomania's clinical features, prevalence, and treatment options, highlighting the potential benefits of behavior therapy and pharmacotherapy but reports no new clinical findings.

This review examines the use of monoaminergic antidepressants for inflammatory skin disorders and reports they may reduce dermatological symptoms, suggesting a potential role beyond treating psychiatric conditions.

This review summarizes preclinical and clinical information on herbal products for hair loss treatment, highlighting their mechanisms, follicular penetration, and potential side effects, suggesting they may offer alternatives to synthetic drugs with fewer side effects.

This review discusses common psychodermatologic conditions and provides practical diagnostic and therapeutic recommendations but reports no new results; the authors emphasize the challenge of treating patients who lack insight into their psychiatric symptoms.

This review discusses the importance of recognizing and treating psychiatric conditions in dermatology patients, offering practical recommendations for dermatologists to manage psychocutaneous diseases effectively, but reports no new clinical results.

This review discusses the cosmetic use and safety of Hypericum Perforatum Extract and Oil, finding that current data are insufficient to support their safety in formulations due to a lack of comprehensive testing.

This review discusses psychocutaneous disorders in children with an emphasis on primary psychiatric disorders manifesting through skin symptoms, but provides no new clinical findings.

This article reviews drug-induced pigmentation and reports no new clinical findings, highlighting difficulty in confirming drug associations due to factors like delayed onset and polypharmacy.

This study provided the first published case reports of alopecia associated with the use of quetiapine.

This review discusses challenges in managing cutaneous drug reactions to anticonvulsants and reports no new clinical findings; the authors emphasize the complexity of discontinuing or rechallenging suspected agents.

Trichotillomania, a disorder where people compulsively pull out their own hair, often starts around age 12, is more common in adult females, and can be treated with behavior therapy and medication.

This study reports that hair analysis could potentially monitor metformin use in diabetic patients, suggesting a possible correlation between daily dose and concentration in dark hair but not in light hair.

This study found that finasteride selectively inhibited UGT1A4 in vitro but is unlikely to cause clinically significant drug interactions mediated through hepatic UGT enzymes in vivo.

This review discusses the range and management of adverse cutaneous reactions to psychotropic medications and emphasizes the need for awareness among clinicians, concluding with a call for careful monitoring and patient education.

This study suggests that spironolactone may cause hormonally associated vestibulodynia and female sexual arousal disorder, with symptoms improving after discontinuation and use of a topical estrogen/testosterone gel.